SEC Comment Letter 0000000000-23-000206 to Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc.
Date: Jan. 6, 2023 · CIK: 0001873835 · Accession: 0000000000-23-000206
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269100
Letter
United States securities and exchange commission logo January 6, 2023 Ilya Rachman Chief Executive Officer Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 Re:Immix Biopharma, Inc. Registration Statement on Form S-3 Filed January 3, 2023 File No. 333-269100 Dear Ilya Rachman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler
Show Raw Text
United States securities and exchange commission logo
January 6, 2023
Ilya Rachman
Chief Executive Officer
Immix Biopharma, Inc.
11400 West Olympic Blvd., Suite 200
Los Angeles, CA 90064
Re:Immix Biopharma, Inc.
Registration Statement on Form S-3
Filed January 3, 2023
File No. 333-269100
Dear Ilya Rachman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler